Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study

We previously reported the immunogenicity of SARS-CoV-2 vaccination within the first year after allogeneic hematopoietic cell transplant (HCT) from CIBMTR SC21-07/BMT CTN 2101. We herein report updated results from the full allogeneic HCT cohort in addition to the autologous HCT and CAR-T cell therapy cohorts.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joshua A. Hill, Michael J. Martens, Jo-Anne H. Young, Kavita Bhavsar, Jianqun Kou, Min Chen, Lik Wee Lee, Aliyah Baluch, Madhav Vishnu Dhodapkar, Ryotaro Nakamura, Kristin Peyton, Zainab Shahid, Paul M. Armistead, Peter Westervelt, John M. McCarty, Joseph Tags: 98 Source Type: research